tiprankstipranks
Nymox Pharmaceutical (NYMXF)
OTHER OTC:NYMXF
US Market

Nymox Pharmaceutical (NYMXF) Income Statement

Compare
141 Followers

Nymox Pharmaceutical Income Statement

Last quarter (Q4 2023), Nymox Pharmaceutical's total revenue was $0.00, a decrease of ― from the same quarter last year. In Q4, Nymox Pharmaceutical's net income was $-5.31M. See Nymox Pharmaceutical’s key income statements, including revenue, expenses, profit, and income.
Income Statement
Dec 23Dec 22Dec 21Dec 20Dec 19
Total Revenue
$ 0.00$ 0.00$ 0.00-$ 116.00K
Gross Profit
$ -11.00K$ -12.00K$ -12.00K-$ 49.00K
Operating Expenses
$ 8.34M$ 6.64M$ 12.49M$ 11.71M$ 13.37M
Depreciation and Amortization
$ 11.00K$ 12.00K$ 12.00K--
EBITDA
$ -8.77M$ -6.52M$ -12.49M$ -11.71M$ -13.12M
Operating Income
$ -8.35M$ -6.65M$ -12.50M$ -11.72M$ -13.32M
Other Income/Expenses
$ -494.00K$ 76.00K$ -33.00K$ -18.00K$ 163.00K
Pretax Income
$ -8.84M$ -6.58M$ -12.54M$ -11.74M$ -13.16M
Net Income
$ -8.84M$ -6.58M$ -12.54M$ -11.74M$ -13.16M
Per Share Metrics
$ ―$ ―$ ―$ ―$ ―
Basic EPS
$ -0.10$ -0.07$ -0.15$ -0.16$ -0.19
Diluted EPS
$ -0.10$ -0.07$ -0.15$ -0.16$ -0.19
Weighted Average Shares Outstanding
91.69M 89.38M 81.98M 73.82M 68.85M
Weighted Average Shares Outstanding (Diluted)
91.69M 89.38M 81.98M 73.82M 68.85M
Currency in USD

Nymox Pharmaceutical Earnings and Revenue History

What am I Missing?
Make informed decisions based on Top Analysts' activity
Know what industry insiders are buying
Get actionable alerts from top Wall Street Analysts
Find out before anyone else which stock is going to shoot up
Get powerful stock screeners & detailed portfolio analysis